Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients
نویسندگان
چکیده
BACKGROUND In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy (CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of the metabolic syndrome (MS) and its components, and to determine whether patients with or without CL had a different prevalence of MA. METHODS We evaluated 345 HIV-infected patients on cART using two different MS definitions (NCEP-ATPIII-2005 and IDF-2005) and the Framingham risk score. RESULTS CL was present in 58.7% of the patients. The prevalence of the MS was 52.2% (ATPIII) and 43.2% (IDF), and it was not significantly different between patients with (W) or without (WT) CL, regardless of the definition used (ATPIII WCL 52.9% vs WT CL 51.1%; p = 0.738; IDF WCL 41.3% vs WTCL 46.0%; p = 0.379). Moderate concordance was observed between the 2 definitions (kappa = 0.484; p < 0.001) and after gender stratification there was good concordance in women (kappa = 0.759; p < 0.001). Patients with CL had lower waist circumference and HDL-C and higher triglycerides levels. In women, CL was significantly associated with MS, hypertriglyceridemia and low HDL cholesterol independently of age, cART and BMI. Patients with CL had a significantly higher risk of coronary heart disease at 10 years, measured by the Framingham risk score, than patients without CL. Those with CL and with MS had higher frequencies of moderate and high risk categories than those without MS. CONCLUSIONS The prevalence of the MS was high in these HIV-infected patients with an age average of 40 years and this finding could explain why HIV patients have an increased risk for cardiovascular disease (CVD).
منابع مشابه
Title: Impact of Lipodystrophy on the Prevalence and Components of Metabolic Syndrome in HIV-infected patients Running title: HIV-Lipodystrophy and Metabolic Syndrome
متن کامل
Metabolic Abnormalities in HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly activ...
متن کاملCardiovascular complications in the acquired immunodeficiency syndrome.
The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease, with increased survival rates. However, the introduction of HAART has generated a contrast in the cardiac manifestations of AIDS. In developed countries, we observed an approximate 30% reduction in the prevalence of HIV-associated cardiomyopathy, possibly related to a...
متن کاملWhat should we know about metabolic syndrome and lipodystrophy in AIDS?
OBJECTIVE Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS A total of 819 patients followed a...
متن کاملEffect of HCV on lipids profile of HIV patients
Abstract Background: There is a high prevalence of HCV-HIV co-infection. In this group of patients increase of insulin resistance and lipodystrophy has been discovered but still sufficient data about the lipid profile has not been performed. In this research we tried compare the lipid profile changes between HIV-HCV patients with HIV and HCV mono infected patients that came to Imam Khomeini c...
متن کامل